Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 2 Alemtuzumab patient and RA patient control pooled demographic and serological data. P value: alemtuzumab patients vs established controls. Values in italics are significant (p < 0.05)

From: Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies

Characteristic Alemtuzumab Treated patients RA Control patients P value
Age (Years)
median, range
65
[45–81]
61.5
[52–79]
0.773
Sex
male/female, %
77%
F
87.5%
F
0.600
Disease Duration (Years)
median, range
31
[23–40]
24.5
[20–41]
0.200
Alemtuzumab total dose (mg)
median, range
60
[18–400]
- -
DAS-28
median, range
3.44
[1.38-5.33]
3.9
[2.03-5.75]
0.743
CRP (mg/L)
median, range
7
[<5-134]
<5
[all <5]
0.001
ESR (mm/hr)
median, range
34
[4–104]
11.5
[2–38]
0.03
HAQ
median, range
2.25
[2–3]
1.69
[0.25-2.13]
0.025
VAS
median, range
25
[2–56]
23
[4–75]
0.847
SJC (n)
median, range
0
[0–2]
1
[0–7]
0.414
TJC (n)
median, range
1
[0–6]
3
[0–20]
0.154
IgG (g/L)
median, range
9.5
[6.2 – 16.6]
9.95
[4.4-16.3]
0.916
IgA (g/L)
median, range
2.6
[1.1 – 4.2]
1.9
[40.4 -3.9]
0.431
IgM (g/L)
median, range
0.85
[0.006 - 3.2]
0.85
[0.3 -2.5]
0.874
RF (IU)
median, range
0
[0–67]
39
[0–275]
0.060
CCP (U/ml)
median, range
0.55
[0–340]
215
[1.2-340]
0.039